21 patients in limbo as talks on funding life-saving drug Respreza break down

Irish patients are set to lose access to life-saving lung disease drug Respreza.

Talks on funding Respreza have collapsed between the HSE and CSL Behring, the pharmaceutical company which makes it.

Twenty-one people suffering from a genetic lung disease called Alpha 1 have been using it for more than 11 years.

They were told last Friday that they will lose access to a vital drug called Respreeza at the end of the month.

Patient Gerry Finnerty from Kinsealy in North Dublin, who is 59, said: "Nobody knows what's going to happen to (us).

"There's no drug there even to ease you off - there's just a striaght trap door: 'There: it's done'."

In a statement last week CSL Behring said: “We remain committed to AATD research to improve the quality of life of people living with the condition. Based on this commitment, we are currently in discussion with health authorities in both the US and Europe to finalise a randomised, non-placebo controlled study design which seeks to demonstrate the long-term safety and efficacy of Respreeza.

“CSL Behring is evaluating clinical sites in Ireland which may then be offered the opportunity to recruit severe AATD patients.”


More in this Section

23-year-old woman due in court in connection with Blanchardstown shooting

Status yellow warnings in place; road users urged to take extra care

Taoiseach to attend summit as Brexit talks move to next phase

23-year-old woman charged in connection with Blanchardstown shooting


Today's Stories

Quarter of early years staff short on references

Man accused of stealing paninis opts for jury trial

€10m works to rectify dangerous bends on Kerry road

RSA honours man left paralysed after traffic collision 11 years ago for road safety work

Lifestyle

Timing is everything as The Frank and Walters revisit 'Grand Parade'

A question of taste: Eileen O'Shea

Eoghan O'Sullivan's picks his highlights of 2017

Learning Points: The ghost of Christmas past is always nostalgia

More From The Irish Examiner